Report that the new corona vaccine developed by Oxford University and AstraZeneca showed high efficacy
Oxford University in the United Kingdom and AstraZeneca, a pharmaceutical company, have released interim data for a
Oxford University breakthrough on global COVID-19 vaccine | University of Oxford
https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine
ChAdOx 1 nCoV-2019 is a vaccine jointly developed by Oxford University and AstraZeneca with the aim of 'permanently providing the new coronavirus vaccine to low- and middle-income countries for non-profit.' Phase III clinical trials of ChAdOx 1 nCoV-2019 were conducted in the United Kingdom, Brazil and South Africa, and 131 of the more than 24,000 subjects were confirmed to be infected with COVID-19.
The vaccine has been administered in two patterns, with efficacy rates of 90% and 62%, respectively, and an average of 70.4%. Those who were highly effective were vaccinated in two separate doses, the first with only half the usual dose and the second with the usual dose. The vaccinated person was not hospitalized or had any serious cases.
This report is just an interim report, and clinical trials of ChAdOx 1 nCoV-2019 are still being conducted in the United States, Kenya, Japan, and India. According to the University of Oxford, approximately 60,000 subjects will be vaccinated with ChAdOx 1 nCoV-2019 by the end of 2020.
Another new corona vaccine whose clinical trials have progressed to Phase III is 'BNT162b2' developed by Pfizer Pharmaceuticals. BNT162b2 has also been reported to be 'more than 90% effective.'
Pfizer Announces Development of 'New Corona Vaccine with Over 90% Preventive Effect' --GIGAZINE
However, it has been pointed out that BNT162b2 has a big problem in vaccine transportation because it needs to be stored at an ultra-low temperature of minus 70 degrees Celsius. On the other hand, Oxford University appeals that ChAdOx 1 nCoV-2019 can be easily administered in the existing medical system and can be stored at 2 ° C to 8 ° C, so it can be transported using the existing logistics system. doing.
Pascal Soriot, CEO of AstraZeneca, said, 'Today is an important milestone in the fight against the pandemic. The effectiveness and safety of ChAdOx 1 nCoV-2019 is very high against COVID-19. We have confirmed that it is effective for and has an immediate impact on public health emergencies. In addition, the simple supply chain of ChAdOx 1 nCoV-2019 and non-profit that promises wide, fair and timely access. With our pledge and commitment, we can supply hundreds of millions of approved vaccines worldwide at affordable prices. '
'These findings show that there are many life-saving and effective vaccines,' said Andrew Polard, director of the vaccine group at Oxford University and principal investigator of the vaccine trial. In addition, one of our vaccination methods was found to be about 90% effective. If this method of administration is used, more people can be vaccinated. We were able to publish the results of the test thanks to the many volunteers who participated in our test and the enthusiastic and talented researchers based around the world. '
Related Posts:
in Science, Posted by log1i_yk